Allergic Rhinitis Drug Market Research & Emerging Trends Report to 2021

Allergic Rhinitis Drug Market Size, Share, Global Trends, Company Profiles,

Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation

and Forecast To 2024

Summary

Allergic Rhinitis (AR) is becoming an increasingly prevalent condition, with the most common

form being moderate to severe in nature (Baena-Cagnani et al., 2015). According to the

European Academy of Allergy and Clinical Immunology (EAACI), 50% of Europeans will

suffer from an allergy by 2027 (Papadopoulos et al., 2012). The allergic rhinitis (AR) market has

declined very slowly over the past decade, as has it become saturated with relatively efficacious

standard therapies, such as antihistamines (AHs), intranasal corticosteroids (INCS), and

leukotriene receptor antagonists (LRAs), and has also been facing increasing generic

competition. Despite the rising prevalence of AR, and a large patient population that is

dissatisfied with the current treatment options, the market size for symptomatic therapies alone is

set to shrink, as the remaining branded products lose patent protection. There is an increasing

shift in the transfer of prescription AR products to over-the-counter (OTC) status, which is

driving patients to pharmacies rather than to physicians, further diluting the prescription AR

market. The immense, crowded generic AR market has been largely unappealing to drug

manufacturers. Consequently, only two symptomatic therapies are expected to launch before

2024.

Highlights

Key Questions Answered

- Allergic Rhinitis symptoms can be controlled in the majority of patients using the current

standard therapies. Nevertheless, in around 20% of people with allergic rhinitis, the disease

remains symptomatic and inadequately controlled. Therefore, there are considerably high unmet

needs within the indication. What are the main unmet needs in this market?

Detailed report at:...